This article is more than 5 years old. Information may no longer be current.

FDA approves recalcitrant nodular acne treatment

The FDA recently approved a brand formulation of isotretinoin as a treatment for severe recalcitrant nodular acne, according to a press release.

CIP-Isotretinoin (Absorica, Cipher Pharmaceuticals) will be distributed in the United States by Ranbaxy Laboratories later this year.

“We are thrilled to make Absorica available as a valuable option for the dermatologist and patients who need treatment for severe recalcitrant nodular acne,” Venkat Krishnan, senior vice president and regional director, Americas for Ranbaxy, said in the release. The treatment is the third Cipher product to receive FDA approval.